«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2020 05

Page:

867-870

Research Field:

Publishing date:

Info

Title:

Progress in the treatment of neuropathic pain in children with cancer

Author(s):

Zhou Lei; Zhou Zejun

Department of Anesthesiology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China.

Keywords:

cancer pain; children; pharmacologic treatment; interventional techniques

PACS:

R730.6

DOI:

10.3969/j.issn.1672-4992.2020.05.042

Abstract:

Cancer pain can be divided into two types:Somatic pain and neuropathic pain.The international association for the study of pain defines neuropathic pain as pain caused by damage or disease that directly affects the somatosensory system.However,not all somatosensory impairment causes neuropathic pain.In pediatric cancer patients,neuropathic pain is caused by a variety of reasons,such as chemotherapy drugs (such as vincristine,cisplatin and paclitaxel£¬et al),spinal cord injury,and direct injury of tumor to tissues and nerves.The incidence of neuropathic pain is lower than that of somatic pain,but it is more difficult to treat,requiring more clinical follow-up,more complex drug administration,and frequent non-drug interventions.In order to better solve the neuropathic pain in children with cancer,this paper intends to review the treatment methods of neuropathic pain in children with cancer,so as to better guide clinical treatment.

References:

£Û1£Ý Bennett MI,Rayment C,Hjermstad M,et al.Prevalence and aetiology of neuropathic pain in cancer patients:A systematic review£ÛJ£Ý.Pain,2012,153(2):359-365.
£Û2£Ý Cooper TE,Heathcote LC,Anderson B,et al.Non-steroidal anti-inflammatory drugs (NSAIDs) forcancer-related pain in children and adolescents£ÛJ£Ý.The Cochrane Database of Systematic Reviews,2017(7):CD012563.
£Û3£Ý H¢|rm¢| A,Aikio O,Hallman M,et al.Intravenous paracetamol decreases requirements of morphine in very preterm infants£ÛJ£Ý.J Pediatr,2016(168):36-40.
£Û4£Ý Wiffen PJ,Cooper TE,Anderson AK,et al.Opioids for cancer-related pain in children andadolescents£ÛJ£Ý.Cochrane Database Syst Rev,2017,7(7):CD012564.
£Û5£Ý Krzysztof Nosek,Wojciech Leppert,Hanna Nosek,et al.Acomparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients£ÛJ£Ý.Drug Design,Drug Des Devel Ther,2017(11):2409-2419.
£Û6£Ý Zwicker JG,Miller SP,Grunau RE,et al.Smaller cerebellar growth and poorer neurodevelopmental outcomes in very preterm infants exposed to neonatal morphine£ÛJ£Ý.J Pediatr,2016(172):81-87.
£Û7£Ý Othman AH,Mohamad MF,Sayed HA.Transdermal fentanyl for cancer pain management in opioid-naive pediatric cancer patients£ÛJ£Ý.Pain Medicine,2016,17(7):1329-1336.
£Û8£Ý ZHAO Dehua,CHU Mingming,CHEN Jing,et al.Meta-analysis and GRADE profile of weak opioids versus low dose strong opioids in the treatment of moderate cancer pain £ÛJ£Ý.Chinese Journal of Hospital Pharmacy,2018,38(18£©:1957-1963.£ÛÕԵ»ª£¬³þÃ÷Ã÷£¬³Â¾²,µÈ.Èõ°¢Æ¬Ò©ÎïÓëµÍ¼ÁÁ¿Ç¿°¢Æ¬Ò©ÎïÖÎÁÆÖжȰ©Í´µÄ £Í£å£ô£á·ÖÎöÓë £Ç£Ò£Á£Ä£Å ÆÀ¼Û£ÛJ£Ý.ÖйúҽԺҩѧÔÓÖ¾£¬2018,38(18£©:1957-1963.£Ý
£Û9£Ý Bandieri E,Romero M,Ripamonti CI,et al.Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain£ÛJ£Ý.J Clin Oncol,2016,34(5):436-442.
£Û10£Ý YANG Dongliang,HE Jiawei,CHAI Lina,et al.Pharmaceuticalcare for the treatment using oxycodone hydrochloride sustainedrelease tablets by rectal administration in children with cancer pain by clinical pharmacists £ÛJ£Ý.Modern Oncology,2018,26(08):1266-1269.£ÛÑÁÁ,ºÎ¼Òΰ,²ñÀöÄÈ,µÈ.¶ùͯ°©Í´ÖÐÑÎËáôÇ¿¼Íª»ºÊÍƬֱ³¦¸øÒ©µÄҩѧ¼à»¤£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ£¬2018,26(08)£º1266-1269.£Ý
£Û11£Ý HE Qiujuan,JIA Yingping,QI Jinlian,et al.Effect of different dosages of hydromorphine hydrochloride on postoperative cancer pain in children £ÛJ£Ý.Guangdong Medical Journal,2018,39(20):3101-3107.£ÛºÎÇï¾ê,¼ÖӢƼ,Æë½ðÁ«,µÈ.²»Í¬¼ÁÁ¿ÑÎËáÇâÂð·ÈͪÓÃÓÚС¶ùÊõºó°©Í´µÄЧ¹û±È½Ï£ÛJ£Ý.¹ã¶«Ò½Ñ§£¬2018,39(20)£º3101-3107.£Ý
£Û12£Ý Rose JB,Finkel JC,Arquedas-Mohs A,et al.Oral tramadol for the treatment of pain of 7-30 days duration in children£ÛJ£Ý.Anesth Analg,2003,969(1):78-81.
£Û13£Ý ZHENG Xiaowei,TAO Gang,KONG Sisi,et al.Progress in clinical application of methadone in cancer pain patients £ÛJ£Ý.China Pharmacist,2018,21(5):908-911.£Û֣СÎÀ,ÌÕ¸Õ,¿×˼˼,µÈ.ÃÀɳͪÔÚ°©Í´»¼ÕßÖеÄÁÙ´²Ó¦ÓýøÕ¹£ÛJ£Ý.Öйúҩʦ£¬2018,21(5)£º908-911.£Ý
£Û14£ÝMadden K,Park M,Liu D,et al.The frequency of QTc prolongation among pediatric and young adult patients receiving methadone for cancer pain £ÛJ£Ý.Pediatr Blood Cancer,2017,64(11):e26614.
£Û15£Ý Rasmussen VF,Lundberg V,Jespersen TW,et al.Extreme doses of intravenous methadone for severe pain in two children with cancer£ÛJ£Ý.Pediatr Blood Cancer,2015,62(6):1087-1090.
£Û16£ÝMadden K,Bruera E.Very-low-dose methadone to treat refractory neuropathic pain in children with cancer£ÛJ£Ý.J Palliat Med,2017,20(11):1280-1283.
£Û17£ÝWiffen PJ,McQuay HJ,Edwards JE,et al.Gabapentin for acute and chronic pain£ÛJ£Ý.Cochrane Database Syst Rev February,2005,20(3):CD005452.
£Û18£Ý YU Xianhua,JIANG Liying.Study on the effect of gabapentin and morphine hydrochloride sustained release tablets in relieving cancer pain£ÛJ£Ý.Chinese Remedies & Clinics,2017,17(12):1824-1826.£ÛÓàÏÊ»¨£¬½ªÀûÓ¢.¼Ó°ÍÅ綡ºÍÑÎËáÂð·È»ºÊÍƬ»º½â°©Í´»¼ÕßÌÛʹЧ¹ûµÄÑо¿£ÛJ£Ý.ÖйúÒ©ÎïÓëÁÙ´²£¬2017,17(12)£º1824-1826.£Ý
£Û19£Ý Sheehy KA,Lippold C,Rice AL,et al.Subanesthetic ketamine for pain management in hospitalized children,adolescents,and young adults:A single-center cohort study £ÛJ£Ý.J Pain Res,2017(10):787-795.
£Û20£Ý Amr YM,Makharita MY.Neurolytic sympathectomy in the management of cancer pain-time effect:a prospective,randomized multicenter study£ÛJ£Ý.J Pain Symptom Manage,2014,48(5):944-956.
£Û21£Ý Klepstad P,Kurita GP,Mercadante S,et al.Evidence of peripheral nerve blocks for cancer-related pain:A systematic review£ÛJ£Ý.Minerva Anestesiol,2015,81(7):789-793.
£Û22£ÝSimic D,Stevic M,Stankovic,et al.The safety and efficacy of the continuous peripheral nerve block in postoperative analgesia of pediatric patients£ÛJ£Ý.Front Med (Lausanne),2018(5):57.
£Û23£ÝZhong W,Yu Z,Zeng JX,et al.Celiac plexus block for treatment of pain associated with pancreatic cancer:A metaanalysis£ÛJ£Ý.Pain Pract,2014,14(1):43-51.
£Û24£ÝXU Fenghe,LIU Chuansheng,YIN Yanwei,et al.Radiofrequency ablation of the abdominal nerve plexus for the treatment of epigastric cancer pain£ÛJ£Ý.Chinese Journal of Pain Medicine,2017,23(12):942-944.£ÛÐì·ïºÍ,Áõ´«Ê¥,ÒüÑàΰ,µÈ.¸¹Ç»Éñ¾­´ÔÉäƵ»ÙËðÊõÓÃÓÚÖÎÁÆÉϸ¹²¿°©Í´µÄÁÙ´²Ñо¿£ÛJ£Ý.ÖйúÌÛʹҽѧÔÓÖ¾£¬2017,23(12):942-944.£Ý
£Û25£ÝCornman-Homonoff J,Holzwanger DJ,Lee KS,et al.Celiac plexus block and neurolysis in the management of chronic upper abdominal pain £ÛJ£Ý.Semin Intervent Radiol,2017,34(4):376-386.
£Û26£ÝRestrepo-Garces CE,Saldarriaga NE,Jaramillo S,et al.Ganglion impar phenol injection in a pediatric patient with refractory cancer pain£ÛJ£Ý.Pain Medicine,2014,15(2):334-336.
£Û27£Ý Risson EG,Serpa AP,Berger JJ,et al.Spinal cord stimulation in the treatment of complex regional pain syndrome type 1:Is trial truly required£ÛJ£Ý.Clin Neurol Neurosurg,2018(171):156-162.
£Û28£Ý Aiyer R,Barkin RL,Bhatia A,et al.A systematic review on the treatment of phantom limb pain with spinal cord stimulation£ÛJ£Ý.Pain Manag,2017,7(1):59-69.
£Û29£Ý Huang Q,Duan W,Sivanesan E,et al.Spinal cord stimulation for pain treatment after spinal cord injury £ÛJ£Ý.Neurosci Bull,2019,35(3):527-539.
£Û30£Ý Solopova IA,Sukhotina IA,Zhvansky DS,et al.Effects of spinal cordstimulation on motor functions in children with cerebral palsy£ÛJ£Ý.Neurosci Lett,2017(639):192-198.
£Û31£Ý Xing F,Yong RJ,Kaye AD,et al.Intrathecal drug delivery and spinal cord stimulation for the treatment of cancer pain £ÛJ£Ý.Curr Pain Headache Rep,2018,22(2):11.
£Û32£Ý Sun KF,Feng WW,Liu YP,et al.Electrical peripheral nerve stimulation relieves bone cancer pain by inducing Arc protein expression in the spinal cord dorsal horn £ÛJ£Ý.J Pain Res,2018(11):599-609.
£Û33£Ý Chakravarthy K,Nava A,Christo PJ,et al.Review of recent advances in peripheral nerve stimulation (PNS)£ÛJ£Ý.Curr Pain Headache Rep,2016,20(11):60.
£Û34£ÝSayed D,Monroe F,Orr WN,et al.Retrospective analysis of intrathecal drug delivery:Outcomes,effificacy,and risk for cancer-related pain at a high volume academic medical center £ÛJ£Ý.Neuromodulation,2018,21(7):660-663.
£Û35£ÝPope JE,Deer TR,Bruel BM,et al.Clinical uses of intrathecal therapy and its placement in the pain care algorithm£ÛJ£Ý.Pain Pract,2016,16(8):1092-1106.
£Û36£ÝCarvajal G,Dupoiron D,Seegers V,et al.Intrathecal drug delivery systems for refractory pancreatic cancer pain:Observational follow-up study over an 11-year period in a comprehensive cancer center £ÛJ£Ý.Anesth Analg,2018,126(6):2038-2046.
£Û37£ÝSUN XY,JIANG J,SHI Q,et al.Clinical application of analgesia in patients with refractory cancer pain£ÛJ£Ý.Jiangsu Med J,2016,42(5):567-569.£ÛËïСӢ£¬½¯¾þ£¬Ê¯ÇÉ£¬µÈ.ÇÊÄÚÕòÍ´ÔÚÍç¹ÌÐÔ°©Í´»¼ÕßµÄÓ¦ÓãÛJ£Ý.½­ËÕÒ½Ò©,2016,42(5):567-569.£Ý
£Û38£ÝCohen M,Zuk J,McKay N,et al.Intrathecal morphine versus extended-release epidural morphine for postoperative pain control in pediatric patients undergoing posterior spinal fusion £ÛJ£Ý.Anesth Analg,2017,124(6):2030-2037.

Memo

Memo:

ÎÀÉú²¿¹ú¼ÒÁÙ´²Öصãר¿Æ½¨ÉèÏîÄ¿£Û±àºÅ£º²ÆÉ磨2011£©170 ºÅ£Ý;ÖØÇìÊÐҽѧÖصãѧ¿ÆÏîÄ¿£Û±àºÅ£ºÓåÎÀ¿Æ½Ì£¨2007£©2£Ý

Common functions

Last Update: 1900-01-01